B All Protokoll Erstellung der Leitlinie
Akute Lymphatische Leukämie (ALL). covid Therapie älterer Patienten mit ALL. Therapie Therapie der reifzelligen B-ALL. Öffentlicher Titel, Therapieoptimierung bei B-ALL und hochmalignem NHL Protokoll, Vollständiges Protokoll nach Amendment IX (passwortgeschützt). und hochmaligner Non-Hodgkin-Lymphome bei. Erwachsenen (ab 18 Jahre). (GMALL-B-ALL/NHL ). KURZPROTOKOLL. Studienleiter. nicht als Protokollpatienten an einer ALL- bzw. Ausnahme: Patienten mit reifzelliger B-ALL werden nicht nach dem Therapieplan der "Non-. B"-ALL, sondern. Merkmale wie die reifzellige B-ALL (ALL = Akute übernommenen, angepassten Protokoll. Wegen timierten GMALL-B-ALL/NHL-Studie für Burkitt-.
Öffentlicher Titel, Therapieoptimierung bei B-ALL und hochmalignem NHL Protokoll, Vollständiges Protokoll nach Amendment IX (passwortgeschützt). Im Rahmen der Therapie gemäß AIEOP-BFM ALL sind dies die Zytostatika Prednison Die eigentliche Induktionstherapie (Protokoll Ia) besteht aus einer intensiven Informationen zur Behandlung von B-ALL finden Sie hier. Die Abgrenzung der reifzelligen Burkitt B-ALL hat eine hohe Relevanz, durch die Anwendung intensiverer Chemotherapie-Schemata nach ALL-BFM Protokoll. Die Therapieabschnitte Konsolidierungs- und Erhaltungstherapie dienen der Aufrechterhaltung der kompletten Remission und werden unter dem Begriff der Postremissionstherapie zusammengefasst. Bei einigen Patienten, insbesondere solchen mit massiver Infiltration oder Fibrose des Knochenmarks, gelingt William Hill Casino Club Flash nicht Punctio Sicca. Leuk Lymphoma Roberts Wort Quiz et al. Zudem wird die FISH-Untersuchung häufig in Ergänzung zur klassischen Chromosomenanalyse eingesetzt, um dort detektierte Aberrationen zu bestätigen und einen Ausgangsbefund Dragon King Verlaufskontrollen zum Nachweis von Resterkrankung unter Therapie zu erhalten. The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia. Ihr Einverständnis gilt für zwölf Monate. Multizentrische Therapieoptimierungsstudie für die Therapie der B-ALL und hochmaligner Non-Hodgkin-Lymphome bei Erwachsenen (ab In dieser Phase können Patienten mit B-ALL an der Randomisierung R-HR teilnehmen. Darauf folgt die Therapiephase „Protokoll III“ (4 Wochen) mit. Die akute lymphatische Leukämie (syn. akute lymphoblastische Leukämie, kurz ALL) ist eine Die reifzellige B-ALL ist eine Sonderform der ALL und kann als die UKALL (United Kingdom ALL Study Group) – Behandlungsprotokoll der UK. Im Rahmen der Therapie gemäß AIEOP-BFM ALL sind dies die Zytostatika Prednison Die eigentliche Induktionstherapie (Protokoll Ia) besteht aus einer intensiven Informationen zur Behandlung von B-ALL finden Sie hier. Die Abgrenzung der reifzelligen Burkitt B-ALL hat eine hohe Relevanz, durch die Anwendung intensiverer Chemotherapie-Schemata nach ALL-BFM Protokoll. Petechien oder Purpura. Pocket Yahtzee Game ;98 9 MSCs erzielen nur eine geringe oder keine Veränderung bezüglich der Gesamtmortalität, eines Rezidivs der malignen Erkrankung und der Inzidenz von akuten GvHD, wenn sie prophylaktisch angewendet werden. Dennoch ist die gezielte Untersuchung auf Aberrationen bei Betting Sites mit schlechtem Ansprechen, Rezidiv oder molekularer Persistenz sowie der potentiell Off-Label- Einsatz zielgerichteter Substanzen im Einzelfall sinnvoll. Kostenloser Qr Scanner K et al. Blutstammzelltransplantation SZT Game Stars Download [ 13 ]. Es ist anzustreben bei Patienten mit molekularem Therapieversagen oder Rezidiv eine weitergehende molekulare Charakterisierung z. Da die Definition dieses Subtyps jedoch auf dem typischen Genexpressionsprofil basiert und die zugrunde liegenden genetischen Veränderungen Quiz Im Internet heterogen sind, ist die Diagnose der Philadelphia-like ALL erschwert. Induktionsphase, Konsolidierungsphase und Re-Induktionsphase werden auch als Intensivphase der Behandlung bezeichnet. Seltener treten - als Varianten der t 8;14 q24;q32 - die Translokationen t 8;22 q24;q11 oder t 2;8 p12;q24 unter Involvierung der Loci der leichten Ketten der Immunglobuline auf. Die ALL ist also eine klonale Wimmelbildspiel Online, d. Studie Was ist das Ziel der Studie? Iacobucci I, Mullighan CG. Bei allen Patienten sollte die Möglichkeit der Biomaterialasservierung z. Philadelphia chromosome-like acute lymphoblastic leukemia. Die Ansprechraten und Langzeitergebnisse mit Blinatumomab sind noch deutlich besser, wenn die Substanz im molekularen Wolfsburg Vs Leverkusen oder molekularem Rezidiv eingesetzt wird. B All Protokoll wenige Patienten versterben aufgrund schwerer in Aplasie erworbener Infektionen während der Behandlung.
It is imperative to carefully monitor children on maintenance therapy for both drug-related toxicity and for compliance with the oral chemotherapy agents used during maintenance therapy.
Importantly, nonadherence to treatment with mercaptopurine in the maintenance phase has been associated with a significant increase in the risk of relapse.
In the past, clinical practice generally called for the administration of oral mercaptopurine in the evening, on the basis of evidence from older studies that this practice may improve EFS.
Some patients may develop severe hematologic toxicity when receiving conventional dosages of mercaptopurine because of an inherited deficiency homozygous mutant of thiopurine S-methyltransferase, an enzyme that inactivates mercaptopurine.
On the basis of these findings, SJCRH modified the agents used in the rotating pair schedule during the maintenance phase.
On the Total XV study, standard-risk and high-risk patients received three rotating pairs mercaptopurine plus methotrexate, cyclophosphamide plus cytarabine, and dexamethasone plus vincristine throughout this treatment phase; low-risk patients received more standard maintenance without cyclophosphamide and cytarabine.
Pulses of vincristine and corticosteroid are often added to the standard maintenance backbone, although the benefit of these pulses within the context of contemporary multiagent chemotherapy regimens remains controversial.
From these studies, it appears that dexamethasone is associated with superior EFS, but also may lead to a greater frequency of steroid-associated complications, including bone toxicity and infections, especially in older children and adolescents.
The benefit of using dexamethasone in children aged 10 to 18 years requires further investigation because of the increased risk of steroid-induced osteonecrosis in this age group.
Maintenance chemotherapy generally continues for 2 to 3 years of continuous CR. On some studies, boys are treated longer than girls;[ 61 ] on others, there is no difference in the duration of treatment based on sex.
Nonadherence to treatment with mercaptopurine during maintenance therapy is associated with a significant risk of relapse. Risk-based treatment assignment is a key therapeutic strategy utilized for children with ALL, and protocols are designed for specific patient populations that have varying degrees of risk of treatment failure.
The Risk-Based Treatment Assignment section of this summary describes the clinical and laboratory features used for the initial stratification of children with ALL into risk-based treatment groups.
For information about clinical trials sponsored by other organizations, refer to the ClinicalTrials. All patients receive a three-drug induction no anthracycline.
After completion of induction, patients are classified into one of three groups on the basis of biology and early response measures:. NCI standard-risk Down syndrome patients who meet definition of standard-risk average will be treated in the same way as non-Down syndrome standard-risk average patients, as detailed above.
All other Down syndrome patients, including NCI high-risk Down syndrome patients, those with unfavorable biology, and those with high day 29 MRD will be considered Down syndrome-high, and will be nonrandomly assigned to receive two cycles of blinatumomab added to a deintensified chemotherapy regimen that omits intensive elements of the augmented BFM treatment backbone.
All patients, regardless of risk group, will receive the same duration of therapy 2 years from the start of interim maintenance 1 phase. This represents a reduction in treatment duration by 1 year for boys compared with standard treatment.
Patients enrolled on this trial will undergo leukapheresis to collect autologous T cells, which will then be sent for manufacturing of tisagenlecleucel.
While awaiting completion of manufacturing, patients will proceed with interim maintenance phase 1 high-dose methotrexate ; this phase may be interrupted as soon as product is available.
Once available, patients will then receive lymphodepleting chemotherapy and infusion of tisagenlecleucel. No further anti-leukemic treatment is to be administered after tisagenlecleucel.
Marrow samples will be obtained at regular intervals postinfusion, beginning at day 29 after tisagenlecleucel administration to assess disease status; tests of peripheral blood will also be sent to screen for evidence of B-cell aplasia.
Patients must have evidence of CDpositivity at diagnosis to enroll on trial. For patients with B-ALL, the protocol is testing whether the addition of two blocks of inotuzumab ozogamicin to a modified-BFM backbone will improve DFS and whether reducing duration of treatment in boys from 3 years from the start of interim maintenance 1 phase to 2 years from the start of that phase does not adversely impact DFS.
All patients receive a four-drug induction including daunorubicin. After completion of induction, subsequent therapy depends on age, biology, and response to therapy.
All patients will receive the same duration of therapy 2 years from the start of interim maintenance 1 phase. This represents a reduction in treatment duration by 1 year for boys, compared with standard treatment.
Patients are assigned an initial risk group by day 10 of therapy. Initial high-risk patients include all other patients lacking very high-risk features, including all patients with T-ALL.
Intensity of induction depends on initial risk group. Initial low-risk patients receive a three-drug induction no anthracycline. All other patients receive a four-drug induction with an anthracycline.
Final risk group, which determines the intensity of postinduction therapy, is assigned on the basis of MRD assessed by next-generation sequencing at the end of induction day 32; first time point and week 10 second time point.
Treatment for all risk groups includes 30 weeks of pegaspargase 15 doses given every 2 weeks during postinduction therapy. In all patients, nadir serum asparaginase activity NSAA is checked before each pegaspargase dose; any patient found to have a nondetectable NSAA is switched to Erwinia asparaginase.
The trial is also piloting a strategy to rechallenge patients with grade 2 hypersensitivity reactions to pegaspargase with pharmacokinetic-monitoring to determine whether such patients will switch to Erwinia or may continue to receive pegaspargase with premedication.
Therefore, all children with acute lymphoblastic leukemia ALL should receive systemic combination chemotherapy together with some form of CNS prophylaxis.
Because the CNS is a sanctuary site i. Historically, survival rates for children with ALL improved dramatically after CNS-directed therapies were added to treatment regimens.
Standard treatment options for CNS-directed therapy include the following:. All of these treatment modalities have a role in the treatment and prevention of CNS leukemia.
The combination of intrathecal chemotherapy plus CNS-directed systemic chemotherapy is standard; cranial radiation is reserved for select situations.
Data suggest that the following groups of patients are at increased risk of CNS relapse:. A major goal of current ALL clinical trials is to provide effective CNS therapy while minimizing neurologic toxic effects and other late effects.
All therapeutic regimens for childhood ALL include intrathecal chemotherapy. Intrathecal chemotherapy is usually started at the beginning of induction, intensified during consolidation and, in many protocols, continued throughout the maintenance phase.
Intrathecal chemotherapy typically consists of one of the following:[ 5 ]. Unlike intrathecal cytarabine, intrathecal methotrexate has a significant systemic effect, which may contribute to prevention of marrow relapse.
In addition to therapy delivered directly to the brain and spinal fluid, systemically administered agents are also an important component of effective CNS prophylaxis.
The following systemically administered drugs provide some degree of CNS prophylaxis:. The proportion of patients receiving cranial radiation therapy has decreased significantly over time.
At present, most newly diagnosed children with ALL are treated without cranial radiation therapy. Ongoing trials seek to determine whether radiation therapy can be eliminated from the treatment of all children with newly diagnosed ALL without compromising survival or leading to increased rate of toxicities from upfront and salvage therapies.
Additional systemic therapy may be required depending on the agents and intensity used. The use of cranial radiation therapy is not a necessary component of CNS-directed therapy for these patients.
Controversy exists as to whether high-risk and very high-risk patients should be treated with cranial radiation therapy, although there is a growing consensus that cranial radiation therapy may not be necessary for most of these patients.
Both the proportion of patients receiving radiation therapy and the dose of radiation administered has decreased over the last two decades.
Larger prospective studies will be necessary to fully elucidate the safety of omitting cranial radiation therapy in CNS3 patients.
The most common acute side effect associated with intrathecal chemotherapy alone is seizures. Patients with ALL who develop seizures during the course of treatment and who receive anticonvulsant therapy should not receive phenobarbital or phenytoin as anticonvulsant treatment, as these drugs may increase the clearance of some chemotherapeutic drugs and adversely affect treatment outcome.
Late effects associated with CNS-directed therapies include subsequent neoplasms, neuroendocrine disturbances, leukoencephalopathy, and neurocognitive impairments.
Subsequent neoplasms are observed primarily in survivors who received cranial radiation therapy. Meningiomas are common and typically of low malignant potential, but high-grade lesions also occur.
Neurocognitive impairments, which can range in severity and functional consequences, have been documented in long-term ALL survivors treated both with and without radiation therapy.
In general, patients treated without cranial radiation therapy have less severe neurocognitive sequelae than irradiated patients, and the deficits that do develop represent relatively modest declines in a limited number of domains of neuropsychological functioning.
Younger age at diagnosis and female sex have been reported in many studies to be associated with a higher risk of neurocognitive late effects. Several studies have also evaluated the impact of other components of treatment on the development of late neurocognitive impairments.
A comparison of neurocognitive outcomes of patients treated with methotrexate versus triple intrathecal chemotherapy showed no clinically meaningful difference.
In a review of a large number of patients treated on Children's Oncology Group COG trials over a year period, T-cell immunophenotype still proved to be a negative prognostic factor on multivariate analysis.
The use of prophylactic cranial radiation therapy in the treatment of patients with T-ALL is declining.
Some groups, such as St. Common therapeutic themes of the intensive chemotherapy regimens used to treat infants with ALL are the inclusion of postinduction intensification courses with high doses of cytarabine and methotrexate.
Infants diagnosed within the first few months of life have a particularly poor outcome. Infants have significantly higher relapse rates than older children with ALL and are at higher risk of developing treatment-related toxicity, especially infection.
Infants with KMT2A gene rearrangements are generally treated on intensified chemotherapy regimens using agents not typically incorporated into frontline therapy for older children with ALL.
However, despite these intensified approaches, EFS rates remain poor for these patients. Evidence intensified chemotherapy regimens for infants with KMT2A rearrangements :.
The optimal treatment for infants without KMT2A rearrangements also remains unclear, in part because of the paucity of data on the use of standard ALL regimens used in older children.
Adolescents and young adults with ALL have been recognized as high risk for decades. Outcomes in almost all studies of treatment are inferior in this age group compared with children younger than 10 years.
In addition to more frequent adverse prognostic factors, patients in this age group have higher rates of treatment-related mortality [ 30 - 33 ] and nonadherence to therapy.
Studies from the United States and France were among the first to identify the difference in outcome based on treatment regimens. Given the relatively favorable outcome that can be obtained in these patients with chemotherapy regimens used for high-risk pediatric ALL, there is no role for the routine use of allogeneic HSCT for adolescents and young adults with ALL in first remission.
Evidence use of a pediatric treatment regimen for adolescents and young adults with ALL :. The reason that adolescents and young adults achieve superior outcomes with pediatric regimens is not known, although possible explanations include the following:[ 36 ].
Adolescents with ALL appear to be at higher risk than younger children for developing therapy-related complications, including osteonecrosis, deep venous thromboses, and pancreatitis.
The improvement in outcome for children and adolescents aged 10 years and older was accompanied by an increased incidence of osteonecrosis. Most cases are diagnosed within the first 2 years of therapy and the symptoms are often recognized during maintenance.
In the past, this subtype of ALL has been recognized as extremely difficult to treat with a poor outcome. Dasatinib has shown significant activity in the CNS, both in a mouse model and a series of patients with CNS-positive leukemia.
Standard-risk patients on both arms will continue to receive imatinib until the completion of all planned chemotherapy 2 years of treatment.
The objective of the standard-risk randomization is to determine whether the less-intensive chemotherapy backbone is associated with a similar DFS but lower rates of treatment-related toxicity compared with the standard therapy EsPhALL chemotherapy backbone.
The prognosis for a child with acute lymphoblastic leukemia ALL whose disease recurs depends on multiple factors. The following two important risk factors after first relapse of childhood ALL are key to determining prognosis and treatment approach:.
Patients who have isolated extramedullary relapse fare better than those who have relapse involving the marrow. For patients with relapsed B-ALL, early relapses fare worse than later relapses, and marrow relapses fare worse than isolated extramedullary relapses.
Age 10 years and older at diagnosis and at relapse have been reported as independent predictors of poor outcome. For patients with B-ALL who were diagnosed at age 18 years or younger and experienced a late relapse, age was not a significant predictor of subsequent outcome when analyzed by quartiles.
However, the outcome for patients aged 18 years and older at time of relapse was significantly inferior to the outcome for patients relapsing at age younger than 18 years Children with Down syndrome and ALL who relapse have generally had inferior outcomes resulting from increased induction deaths, treatment-related mortality, and relapse.
The COG reported that risk group classification at the time of initial diagnosis was prognostically significant after relapse; patients who met National Cancer Institute NCI standard-risk criteria at initial diagnosis fared better after relapse than did NCI high-risk patients.
Patients with marrow relapses who have persistent morphologic disease at the end of the first month of reinduction therapy have an extremely poor prognosis, even if they subsequently achieve a second complete remission CR.
Changes in mutation profiles from diagnosis to relapse have been identified by gene sequencing. The presence of RAS pathway mutations at relapse was associated with early relapse.
However, presence of RAS pathway mutations at relapse was not an independent predictor of outcome. Patients with ETV6-RUNX1 -positive ALL appear to have a relatively favorable prognosis at first relapse, consistent with the high percentage of such patients who relapse more than 36 months after diagnosis.
Immunophenotype is an important prognostic factor at relapse. Patients with T-ALL who experience a marrow relapse isolated or combined at any time during treatment or posttreatment are less likely to achieve a second remission and long-term EFS than are patients with B-ALL.
Standard treatment options for first bone marrow relapse include the following:. Initial treatment of relapse consists of reinduction therapy to achieve a second CR.
The potential benefit of mitoxantrone in relapsed ALL regimens requires further investigation. Patients with relapsed T-ALL have much lower rates of achieving second CR with standard reinduction regimens than do patients with B-cell phenotype.
Reinduction failure is a poor prognostic factor, but subsequent attempts to obtain remission can be successful and lead to survival after HSCT, especially if MRD becomes low or nondetectable refer to the Late-relapsing B-ALL section of this summary for more information on MRD risk stratification.
Approaches have traditionally included the use of drug combinations distinct from the first attempt at treatment; these regimens often contain newer agents under investigation in clinical trials.
Although survival is progressively less likely after each attempt, two to four additional attempts are often pursued, with diminishing levels of success measured after each attempt.
For B-ALL patients with an early marrow relapse, allogeneic transplant from an HLA-identical sibling or matched unrelated donor that is performed in second remission has been reported in most studies to result in higher leukemia-free survival than a chemotherapy approach.
A number of studies have shown that patients with a late marrow relapse who have high end-reinduction MRD have better outcomes if they receive an allogeneic HSCT in second CR after achieving low or nondetectable MRD status.
For patients with T-ALL who achieve remission after bone marrow relapse, outcomes with postreinduction chemotherapy alone have generally been poor,[ 5 ] and these patients are usually treated with allogeneic HSCT in second CR, regardless of time to relapse.
Although there are no studies directly comparing chemotherapy with HSCT for patients in third or subsequent CR, because cure with chemotherapy alone is rare, transplant has generally been considered a reasonable approach for those achieving remission.
Given the poor outcomes for multiply relapsed B-ALL patients who are treated with chemotherapy followed by HSCT, CAR T-cell therapy has been tested in this population and has resulted in high rates of remission and improved short-term survival long-term follow-up pending; refer to the CAR T-cell therapy section of this summary for more information.
Immune therapies such as blinatumomab and inotuzumab have also greatly facilitated the achievement of remission, which has generally been followed by HSCT.
An expert panel review of indications for HSCT was published in Two registry studies and a small randomized trial showed that transplant conditioning regimens that include TBI resulted in higher cure rates than chemotherapy-only preparative regimens.
Fractionated TBI total dose, 12—14 Gy is often combined with cyclophosphamide, etoposide, thiotepa, or a combination of these agents. Study findings with these combinations have generally resulted in similar rates of survival,[ 76 - 78 ] although one study suggested that if cyclophosphamide is used without other chemotherapy drugs, a dose of TBI in the higher range may be necessary.
On the other hand, when cyclophosphamide and etoposide were used with TBI, doses above 12 Gy resulted in worse survival resulting from excessive toxicity.
Remission status at the time of transplantation has long been known to be an important predictor of outcome, with patients not in CR at HSCT having very poor survival rates.
When patients have received two to three cycles of chemotherapy in an attempt to achieve an MRD-negative remission, the benefit of further intensive therapy for achieving MRD negativity must be weighed against the potential for significant toxicity.
In addition, there is not clear evidence showing that MRD positivity in a patient who has received multiple cycles of therapy is a biological disease marker for poor outcome that cannot be modified, or whether further intervention bringing such patients into an MRD negative remission will overcome this risk factor and improve survival.
One study showed higher sensitivity for predicting relapse using next-generation sequencing assays than with flow cytometry, especially early after HSCT.
Survival rates after matched unrelated donor and umbilical cord blood transplantation have improved significantly over the past decade and offer an outcome similar to that obtained with matched sibling donor transplants.
Another CIBMTR study suggested that outcome after one- or two-antigen mismatched cord blood transplants may be equivalent to that for a matched family donor or a matched unrelated donor.
Most studies of pediatric and young adult patients that address this issue suggest an effect of both acute and chronic GVHD in decreasing relapse.
To harness this GVL effect, a number of approaches to prevent relapse after transplantation have been studied, including withdrawal of immune suppression or donor lymphocyte infusion and targeted immunotherapies, such as monoclonal antibodies and natural killer cell therapy.
The use of post-HSCT intrathecal chemotherapy chemoprophylaxis is controversial. However, many patients will be unable to undergo a second HSCT procedure because of failure to achieve remission, early toxic death, or severe organ toxicity related to salvage chemotherapy.
Reduced-intensity approaches can also cure a percentage of patients when used as a second allogeneic transplant approach, but only if patients achieve a CR confirmed by flow cytometry.
A small series has shown survival in selected patients using chemotherapy alone or chemotherapy followed by a second transplant. The following two immunotherapeutic agents have been studied for the treatment of patients with refractory B-ALL:.
Chimeric antigen receptor CAR T-cell therapy is a therapeutic strategy for pediatric B-ALL patients with refractory disease or those in second or subsequent relapse.
This treatment involves engineering T cells with a CAR that redirects T-cell specificity and function. Treatment with CAR T cells has been associated with cytokine release syndrome, which can be life-threatening.
Severe cytokine release syndrome has been effectively treated with tocilizumab, an anti—interleukin-6 receptor IL-6R antibody. Neurotoxicity, including aphasia, altered mental status, and seizures, has also been observed with CAR T-cell therapy, and the symptoms usually resolve spontaneously.
Other CAR T-cell therapy side effects include coagulopathy, hemophagocytic lymphohistiocytosis HLH —like laboratory changes, and cardiac dysfunction.
Published trials have involved the use of two types of costimulatory molecules, BB and CD CDbased approaches have led to high rates of remission, but CAR T cells in these trials rarely persist longer than 1 to 2 months, necessitating HSCT for long-term survival.
Studies looking specifically at inotuzumab rescue of CDnegative relapse have not been published, but two groups have reported high rates of subsequent achievement of remission and survival, generally when CD22 CAR T-cell therapy is followed by HSCT therapy.
With improved success in treating children with ALL, the incidence of isolated extramedullary relapse has decreased. Patients with an isolated CNS relapse who show greater than 0.
While the prognosis for children with isolated CNS relapse had been quite poor in the past, aggressive systemic and intrathecal therapy followed by cranial or craniospinal radiation has improved the outlook, particularly for patients who did not receive cranial radiation during their first remission.
The use of transplantation to treat isolated CNS relapse occurring less than 18 months from diagnosis, especially T-cell CNS relapse, requires further study.
The results of treatment of isolated testicular relapse depend on the timing of the relapse. Standard treatment options in North America for childhood ALL that has recurred in the testes include the following:.
Standard approaches for treating isolated testicular relapse in North America include local radiation therapy along with intensive chemotherapy.
In some European clinical trial groups, orchiectomy of the involved testicle is performed instead of radiation.
Biopsy of the other testicle is performed at the time of relapse to determine if additional local control surgical removal or radiation is to be performed.
A study that looked at testicular biopsy at the end of frontline therapy failed to demonstrate a survival benefit for patients with early detection of occult disease.
There are limited clinical data concerning outcome without the use of radiation therapy or orchiectomy.
Treatment protocols that have tested this approach have incorporated intensified dosing of chemotherapy agents e. Multiple clinical trials investigating new agents and new combinations of agents are available for children with second or subsequent relapsed or refractory ALL and should be considered.
These trials are testing targeted treatments specific for ALL, including monoclonal antibody—based therapies and drugs that inhibit signal transduction pathways required for leukemia cell growth and survival.
Multiple clinical trials investigating new agents, new combinations of agents, and immunotherapeutic approaches are available.
Refer to the ClinicalTrials. The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available.
This section describes the latest changes made to this summary as of the date above. Added text to state that in another study, doses of pegaspargase were reduced in an attempt to decrease toxicity.
While lower doses were successful in maintaining appropriate asparaginase levels of more than 0. This study did not report on the impact of lower doses of pegaspargase on event-free survival cited Kloos et al.
Added text about the results of the Nordic Society for Pediatric Hematology and Oncology ALL protocol that evaluated minimal residual disease before transplantation in children with very high-risk ALL cited Ifversen et al.
Added Ifversen et al. Added Yeshurun et al. This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of childhood acute lymphoblastic leukemia.
It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.
Board members review recently published articles each month to determine whether an article should:. Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in the published articles and determine how the article should be included in the summary.
Any comments or questions about the summary content should be submitted to Cancer. Do not contact the individual Board Members with questions or comments about the summaries.
Board members will not respond to individual inquiries. Some of the reference citations in this summary are accompanied by a level-of-evidence designation.
These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches.
PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated.
Permission to use images outside the context of PDQ information must be obtained from the owner s and cannot be granted by the National Cancer Institute.
Information about using the illustrations in this summary, along with many other cancer-related images, is available in Visuals Online , a collection of over 2, scientific images.
More information on insurance coverage is available on Cancer. More information about contacting us or receiving help with the Cancer. Questions can also be submitted to Cancer.
Menu Contact Dictionary Search. Understanding Cancer. What Is Cancer? Cancer Statistics. Cancer Disparities.
Cancer Causes and Prevention. Risk Factors. Cancer Prevention Overview. Cancer Screening Overview. Screening Tests.
Diagnosis and Staging. Questions to Ask about Your Diagnosis. Types of Cancer Treatment. Side Effects of Cancer Treatment.
Clinical Trials Information. A to Z List of Cancer Drugs. Questions to Ask about Your Treatment. Feelings and Cancer. Adjusting to Cancer. Day-to-Day Life.
Support for Caregivers. Questions to Ask About Cancer. Choices for Care. Talking about Your Advanced Cancer. Planning for Advanced Cancer.
Advanced Cancer and Caregivers. Questions to Ask about Advanced Cancer. Managing Cancer Care. Finding Health Care Services. Advance Directives.
Using Trusted Resources. Coronavirus Information for Patients. Clinical Trials during Coronavirus.
Adolescents and Young Adults with Cancer. Reports, Research, and Literature. Cancers by Body Location. Late Effects of Childhood Cancer Treatment.
Pediatric Supportive Care. Rare Cancers of Childhood Treatment. Childhood Cancer Genomics. Study Findings. Metastatic Cancer Research.
Intramural Research. Extramural Research. Cancer Research Workforce. Cancer Biology Research. Cancer Genomics Research. Research on Causes of Cancer.
Cancer Diagnosis Research. Cancer Prevention Research. Cancer Treatment Research. Cancer Health Disparities.
Childhood Cancers Research. Global Cancer Research. Cancer Research Infrastructure. Clinical Trials. Frederick National Laboratory for Cancer Research.
Bioinformatics, Big Data, and Cancer. Annual Report to the Nation. Research Advances by Cancer Type. Stories of Discovery.
Milestones in Cancer Research and Discovery. Director's Message. Budget Proposal. Stories of Cancer Research. Driving Discovery.
Highlighted Scientific Opportunities. Research Grants. Research Funding Opportunities. Cancer Grand Challenges. Research Program Contacts.
Funding Strategy. Grants Policies and Process. Introduction to Grants Process. NCI Grant Policies. Legal Requirements.
Step 3: Peer Review and Funding Outcomes. Manage Your Award. Grants Management Contacts. Prior Approvals. Annual Reporting and Auditing.
Transfer of a Grant. Grant Closeout. Cancer Training at NCI. Resources for Trainees. Funding for Cancer Training. Building a Diverse Workforce.
Resources for News Media. Media Contacts. Cancer Reporting Fellowships. Advisory Board Meetings. Social Media Events. Cancer Currents Blog.
Contributing to Cancer Research. Strategic Planning. Deputy Director's Page. Previous NCI Directors.
Advisory Boards and Review Groups. NCI Congressional Justification. Current Congress. Committees of Interest. Legislative Resources. Recent Public Laws.
Search Search. Adult ALL Treatment. Adult AML Treatment. Hairy Cell Leukemia Treatment. Childhood ALL Treatment. Childhood AML Treatment.
Prenatal exposure to x-rays. Postnatal exposure to high doses of radiation e. Previous treatment with chemotherapy.
Genetic conditions that include the following: Down syndrome. Refer to the Down syndrome section of this summary for more information. Neurofibromatosis NF1.
Association with genetic syndromes. Increased risk can be associated with the genetic syndromes listed above in which ALL is observed, although it is not the primary manifestation of the condition.
Common alleles. Another category for genetic predisposition includes common alleles with relatively small effect sizes that are identified by genome-wide association studies.
Genome-wide association studies have identified a number of germline inherited genetic polymorphisms that are associated with the development of childhood ALL.
ARID5B is a gene that encodes a transcriptional factor important in embryonic development, cell type—specific gene expression, and cell growth regulation.
Germline variants that cause pathogenic changes in genes associated with ALL and that are observed in kindreds with familial ALL i.
A germline variant in PAX5 that substitutes serine for glycine at amino acid and that reduces PAX5 activity has been identified in several families that experienced multiple cases of ALL.
Provisional entity: Early T-cell precursor lymphoblastic leukemia. Bilineal leukemias in which there are two distinct populations of cells, usually one lymphoid and one myeloid.
Biphenotypic leukemias in which individual blast cells display features of both lymphoid and myeloid lineage. Genomics of childhood ALL The genomics of childhood ALL has been extensively investigated, and multiple distinctive subtypes have been defined on the basis of cytogenetic and molecular characterizations, each with its own pattern of clinical and prognostic characteristics.
Subclassification of childhood ALL. Chromosome number. High hyperdiploidy 51—65 chromosomes. Treatment regimen. Notch pathway signaling.
T-ALL cases with SPI1 fusions had a particularly poor prognosis; six of seven affected individuals died within 3 years of diagnosis of early relapse.
Genes encoding epigenetic regulators e. Introduction to Risk-Based Treatment Children with acute lymphoblastic leukemia ALL are usually treated according to risk groups defined by both clinical and laboratory features.
Factors used by the COG to determine the intensity of induction include the following: Immunophenotype. The presence or absence of extramedullary disease.
Steroid pretreatment. The presence or absence of Down syndrome. Patient and clinical disease characteristics. Leukemic characteristics. Response to initial treatment.
Age at diagnosis. WBC count at diagnosis. Central nervous system CNS involvement at diagnosis. Testicular involvement at diagnosis.
Down syndrome trisomy Race and ethnicity. Weight at diagnosis and during treatment. Infants younger than 1 year. ALL subtype. The reason for better outcomes in white and Asian children than in black and Hispanic children is at least partially explained by the different spectrum of ALL subtypes.
Treatment adherence. Differences in outcome may also be related to treatment adherence, as illustrated by a study of adherence to oral mercaptopurine 6-MP in maintenance therapy.
In the first report from the study, there was an increased risk of relapse in Hispanic children compared with non-Hispanic white children, depending on the level of adherence, even when adjusting for other known variables.
Ancestry-related genomic variations may also contribute to racial and ethnic disparities in both the incidence and outcome of ALL. Three studies did not demonstrate an independent effect of obesity on EFS.
However, obese patients at diagnosis who then normalized their weight during the premaintenance period of treatment had outcomes similar to patients with normal weight at diagnosis.
In a retrospective study of patients treated at a single institution, obesity at diagnosis was linked to an increased risk of having minimal residual disease MRD at the end of induction and an inferior EFS.
OS was lower in patients with a high BMI, primarily resulting from treatment-related mortality and inferior salvage after relapse.
Male sex. Older age. Mediastinal mass. MRD determination. Day 7 and day 14 bone marrow responses. Peripheral blood response to steroid prophase.
Peripheral blood response to multiagent induction therapy. Peripheral blood MRD before end of induction day 8, day Persistent leukemia at the end of induction induction failure.
For patients with B-ALL, evaluating MRD at two time points end-induction and end-consolidation can identify the following three prognostically distinct patient subsets:[ ] Low or undetectable end-induction MRD: best prognosis.
Detectable or high MRD at end-consolidation week 12 of therapy : worst prognosis. High risk high MRD after the second cycle of chemotherapy.
In a COG study involving nearly 2, children with ALL, the presence of MRD in the peripheral blood at day 8 was associated with adverse prognosis; increasing MRD levels were associated with a progressively poorer outcome.
A smaller study assessed the prognostic significance of peripheral blood MRD at day 15 after 1 week of a steroid prophase and 1 week of multiagent induction therapy.
T-cell phenotype. Unfavorable biology. KMT2A rearrangement. The authors suggested that using both morphologic and MRD criteria to define induction failure would more precisely identify patients with poor outcomes.
Morphology and MRD were concordant in However, only Presence of extramedullary disease. Down syndrome. Infants with KMT2A rearrangements.
Patients with initial induction failure. Standard risk: Patients who are MRD negative i. Patients with a poor response to the prednisone prophase are also considered high risk, regardless of subsequent MRD.
Favorable cytogenetic features include the following: Hyperdiploidy with double trisomies of chromosomes 4 and 10 double trisomy ; or ETV6-RUNX1 fusion.
KMT2A rearrangements. Standard risk. CNS1 status and no testicular disease at diagnosis. No steroid therapy pretreatment. Intermediate risk.
Any CNS status at diagnosis. Very high risk. Any CNS status. Overt testicular leukemia evidenced by ultrasonography.
Very high-risk features must be absent. Final low risk: Initial low risk and MRD less than 0. Final high risk: Initial low risk with MRD greater than 0.
Final very high risk: Initial very high-risk patients or any patient with MRD greater than 0. Special Considerations for the Treatment of Children With Cancer Because treatment of children with acute lymphoblastic leukemia ALL entails complicated risk assignment and therapies and the need for intensive supportive care e.
Pediatric surgical subspecialists. Radiation oncologists. Pediatric intensivists. Rehabilitation specialists. Pediatric nurse specialists.
Social workers. Child life professionals. Remission induction chemotherapy at the time of diagnosis. Postinduction therapy after achieving complete remission.
Maintenance therapy. Corticosteroid either prednisone or dexamethasone. Intrathecal chemotherapy. The Children's Cancer Group conducted a randomized trial that compared dexamethasone and prednisone in standard-risk B-ALL patients receiving a three-drug induction without an anthracycline.
Dexamethasone was associated with a higher frequency of reversible steroid myopathy and hyperglycemia. No significant differences in rates of infection during induction were observed between the two randomized arms.
The trial demonstrated that dexamethasone was associated with a more favorable outcome than prednisolone in all patient subgroups. Patients who received dexamethasone had a significantly lower incidence of both central nervous system CNS and non-CNS relapses than did patients who received prednisolone.
Dexamethasone was associated with a higher incidence of steroid-associated behavioral problems and myopathy, but an excess risk of osteonecrosis was not observed.
There was no difference in induction death rates between the randomized groups. Dexamethasone was associated with higher incidence of life-threatening events primarily infections , resulting in a significantly higher induction death rate 2.
There was no difference in rates of osteonecrosis between the randomized groups. No difference in overall survival OS was observed based on steroid randomization, although the study was not sufficiently powered to detect small differences in OS.
Dexamethasone was associated with a higher rate of infection, but there was no difference in the induction death rate when comparing dexamethasone and prednisone.
For patients who were younger than 10 years at diagnosis, there was a significant interaction between the corticosteroid and methotrexate randomizations; however, the best outcome for this group of patients was observed in those who received both dexamethasone during induction and high-dose methotrexate during interim maintenance.
The corticosteroid randomization was closed early for patients aged 10 years or older at diagnosis because of excessive rates of osteonecrosis in patients randomly assigned to dexamethasone; however, it did not appear that there was any EFS benefit associated with dexamethasone in these older patients 5-year EFS rates of Pegaspargase PEG-asparaginase.
Asparaginase Erwinia chrysanthemi Erwinia L-asparaginase. Native Escherichia coli E. Each agent was administered for a week period after the achievement of CR.
There was no difference in rates of asparaginase-related toxicities, including hypersensitivity, pancreatitis, and thromboembolic complications.
Similar outcome and similar rates of asparaginase-related toxicities were observed for both groups of patients. Signing is optional, indicating an intention to ratify the Protocol.
Ratification means that a state is legally bound by the provisions of the treaty. For Annex I parties e. Iceland was the 55th state to ratify, fulfilling the first condition for coming-into-force.
With Russia's ratification the "55 percent of carbon dioxide emissions of the Parties included in Annex I" clause was satisfied and the treaty was brought into force, effective 16 February As of July , states have accepted the Doha amendment, but it has not entered into force.
From Wikipedia, the free encyclopedia. Wikipedia list article. Annex B parties with binding targets in the second period.
Annex B parties with binding targets in the first period but not the second. Annex B parties with binding targets in the first period but which withdrew from the Protocol.
Signatories to the Protocol that have not ratified. Other UN member states and observers that are not party to the Protocol.
A declaration was made upon ratifacation that an agreement had been reached by the states to jointly meet their reduction commitments under the Protocol, as permitted by Article 4 of the Protocol.
The 13 member states that entered the union later did not participate in this joint agreement, and retained their individual Kyoto targets if applicable.
An agreement was subsequently reached by the states to jointly meet their reduction commitments under the amended Protocol.
Both took on targets under the Doha Amendment. It refused to ratify the Convention, as it objected to its listing in the annexes. Retrieved 12 October Retrieved 28 October United Nations Treaty Series.
Retrieved 24 July Retrieved 1 April United Nations. Retrieved 28 April Retrieved 26 April Official Journal of the European Communities.
L Pajhwok Afghan News. Retrieved 4 April Retrieved 1 October Retrieved 30 April Retrieved 15 May European Commission.
Retrieved 29 April Official Journal of the European Union. Retrieved 21 September European Union. Retrieved 22 September Retrieved 27 April Retrieved 1 May English translation: What's after Kyoto protocol for Turkey?
Retrieved 2 April Retrieved 27 January Categories : Climate change policy Climate change-related lists Lists of parties to treaties.
Hidden categories: CS1 errors: missing periodical CS1: long volume value Articles with Turkish-language sources tr Webarchive template wayback links Articles with short description Short description is different from Wikidata Use dmy dates from January Namespaces Article Talk.
B All Protokoll VideoALL: Cytogenetics and T-Cell Versus B-Cell Induction Strategies
B All Protokoll - InhaltsverzeichnisZum anderen kann im Einzelfall bei Patienten mit sehr protrahierter Aktivität und Toxizitäten für nachfolgende Blöcke eine Dosisreduzierung erwogen werden. Druckfassung Kommentieren. Tasian SK et al. Regelwerk Interessenkonflikte. Deswegen sehen die bisherigen Therapiekonzepte für diese Patienten primär eine intensivere Behandlung vor. Lymphknoten, Milz und nicht lymphatischen Organe z.
Pui et al reported an event free survival at 5 years of Overall event free survival was estimated to be Patients were stratified and treated according to risk standard, medium and high risk.
The published results of the ALL-BFM95 study did not demonstrate a benefit from the two randomisations cytarabine in the intensification phase and pulse during maintenance.
If minimal residual disease MRD testing is available, then the incorporation of these results appears justified on the published data, at least for the pre-B ALL group.
Pegasparaginase is given as an alternative preparation and has the advantage of longer half life, lower immunogenicity and more efficient asparaginase depletion than standard preparatations.
MRD testing has become a standard part of managing children with acute lymphoblastic leukaemia, but is not generally available outside clinical trials.
With no standard care approach to ALL in the younger population of patients defined, which risk criteria to utilize is not yet defined.
ALL BFM is a high intensity regimen with the published results for patients up to the age of 18 years. It is unknown what is the safe upper age limit in tolerability for this regimen.
The project goal is the provision of a sustainable model for evidence retrieval to ensure ongoing currency of content. Occasionally the searches may not display correctly or take too long to load and will eventually timeout.
You can rectify this by using Firefox, Safari or Google chrome. It is always a good idea to clear the cache regularly to ensure you are getting the most up to date search.
If you identify any new articles that you believe should be included in the content, please use the feedback button below to inform us of the name of the article s.
Any clinician medical oncologist, haematologist, radiation oncologist, medical physicist, radiation therapist, pharmacist or nurse seeking to apply or consult this protocol is expected to use independent clinical judgement in the context of individual clinical circumstances to determine any patient's care or treatment.
Send feedback for this page. The currency of this information is guaranteed only up until the date of printing, for any updates please check:.
Acute lymphoblastic leukaemia BFM treatment overview. ID: v. This treatment should only be carried out in a major centre as intense monitoring and support is required Units are encouraged to enrol eligible patients age 15 to 40 on a similar approved ANZCHOG paediatric protocol.
Related pages: Asparaginase. Due to falling blood values after treatments, regular blood tests are taken. Transfusions and treatment for infections are also necessary.
This is due to nausea, vomiting, mucositis, dry mouth, pain, constipation, and sensory changes. Leukemia patients rarely need tube-feeding to meet their nutritional needs.
Steroids can lead to an increase in appetite and good nutritional guidance is important. Vincristine can cause neuromuscular manifestations.
Pain often starts with sensory disturbances and paresthesia. The neuromuscular side effects are muscle atrophy, loss of deep tendon reflexes, bone pain, jaw pain, and tracheal pain.
Vincristine can also lead to drooping eyelids ptosis. Side effects eventually disappear after cessation of the drug but may remain longer in some patients.
The degree of soreness is individual. Prophylactic oral hygiene is practiced during the entire treatment. For sore mucosa in the rectum, lubrication is necessary.
Bathing in green soap is also soothing. Temperatures should not be taken rectally, nor should patients get suppositories, enemas, etc.
The nausea will diminish days after finishing a course of chemotherapy depending on the drug. Parents will receive a prescription for anti-nausea medication.
Because of large steroid doses, the child is susceptible to gastritis. Cardiac testing is more important the longer the treatment.
Use of steroids makes the child susceptible to dramatic changes of mood. This may be a great burden for both the child and the rest of the family.
Treatment for ALL usually leads to isolation from the local community. The child may not be included in normal play. Ten to fourteen days after finishing a course of chemotherapy, the blood values are at their lowest.
This is when the child is most susceptible to infection. School-age children may go to school if they feel well enough. Otherwise, the child receives home-schooling.
Oslo University Hospital shall not be liable for any loss whether direct, indirect, incidental or consequential, arising out of access to, use of, or reliance upon any of the content on this website.
With high-dose cytarabine, prednisolone eye drops are given to prevent chemical conjunctivitis during and for 2 days after a treatment.
Creatinine and serum concentration of methotrexate MTX should be monitored regularly. Calcium folinate "rescue" is given as described in the treatment plan depending on serum MTX.
Furosemide is given as necessary. For asparaginase, be prepared for anaphylaxis. Check urine days per week and look for glucosuria and hyperglycemia.
With etoposide, be prepared for anaphylaxis and hypotension. Consolidation Standard and intermediate risk Consolidation treatment consists of: Mercaptopurine tablets orally.Cognitive function for both groups assessed at a median of 6 years postdiagnosis was in the average range, with Gmx Einloggen Ohne Werbung subtle differences noted between the groups in Secret Kosten skills. The Ph chromosome t 9;22 q Montreal: UNEP. English translation: What's after Kyoto protocol for Turkey? Annex B parties with binding targets in the second period. Special precautions apply. Patients who have a traumatic lumbar puncture showing blasts at the time of diagnosis may have an increased risk Cadino Royale CNS relapse. Secretary-General of the United Nations. Because of large steroid doses, the child is susceptible to gastritis.